FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Fate Therapeutics
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Nurix Therapeutics, Inc.
University of Chicago
AstraZeneca
University of Chicago
AIDS Malignancy Consortium
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center